Explanipedia

Long-Term Recurrence Risk, Metastatic Potential, and Length of Cystoscopic Surveillance of Low-Grade Nonmuscle-Invasive Bladder Cancer Open

Eunice Villegas, Katherine Lajkosz, Shayan Din, Cynthia Kuk, Amy Chan , et al. · 2024

This study with long-term data challenges the assumption that primary TaLG NMIBC nearly never progresses to lethal disease if followed long enough. However, the risk of BC-related mortality is extremely low in patients who are recurrence f…

Challenging Cases in Urothelial Cancer: Case 33 Open

Mark S. Soloway, Neil A. Abrahams, Nat E. Pinnar · 2024

A 75 year old previously healthy woman was admitted to the hospital with a urinary tract infection which required one week admission.As part of the investigation, she had a CT scan of the abdomen and pelvis which revealed a mass in the ant…

Challenging Cases in Urothelial Cancer: Case 32 Open

Mark S. Soloway, Neil A. Abrahams · 2024

The International Bladder Cancer Group Intermediate-Risk Non-muscle Invasive Bladder Cancer Scoring System Predicts the Need for Intervention for Patients on Active Surveillance Open

Roberto Contieri, Wei Shen, Nicolò Maria, Giovanni Lughezzani, Valentina Grajales , et al. · 2024

Challenging Cases in Urothelial Cancer: Case 31: LG Ta Bladder Cancer Open

Mark S. Soloway, Neil A. Abrahams · 2024

Challenging Cases in Urothelial Cancer: Case 30: Rare Complication of BCG Open

Mark S. Soloway · 2023

Challenging Cases in Urothelial Cancer: Case 29 Open

Mark S. Soloway · 2023

Challenging Cases in Urothelial Cancer: Case 28: Lynch Syndrome Open

Mark S. Soloway · 2023

Challenging Cases in Urothelial Cancer: Case 27 Open

Mark S. Soloway, Neil A. Abrahams · 2023

Inflection points in urology as witnessed by Mark Soloway Part 2: Prostate and kidney cancers Open

Mark S. Soloway · 2023

Inflection Points in Urology as Witnessed by Mark Soloway Part 1: Bladder cancer Open

Mark S. Soloway · 2023

Targeting hyaluronic acid synthase-3 (HAS3) for the treatment of advanced renal cell carcinoma Open

Jiaojiao Wang, Andre R. Jordan, Huabin Zhu, Sarrah L. Hasanali, Eric F. Thomas , et al. · 2022

Background Hyaluronic acid (HA) promotes cancer metastasis; however, the currently approved treatments do not target HA. Metastatic renal carcinoma (mRCC) is an incurable disease. Sorafenib (SF) is a modestly effective antiangiogenic drug …

Challenging Cases in Urothelial Cancer: Case 26 Open

Mark S. Soloway · 2022

This 37 year old healthy appearing man had a seven month history of intermittent gross hematuria.He has no voiding problems beside hematuria.He has hypertension and takes losartan and hydrochlorothiazide.He has not had surgery.He has never…

Challenging Cases in Urothelial Cancer: Case 25 Open

Mark S. Soloway, Neil A. Abrahams · 2022

Challenging Cases in Urothelial Cancer: Case 24 Open

Mark S. Soloway, Neil A. Abrahams · 2022

This 73-year-old man presented to his primary physician with a one month history of intermittent gross hematuria.He was promptly referred by an excellent community urologist.A CT scan indicated high grade right ureteral dilatation to the l…

Challenging Cases in Urothelial Cancer: Case 22 Open

Mark S. Soloway · 2021

This is a 58 year old non smoker who had intermittent gross hematuria for one year.He did not have a good reason for not seeking medical attention.He was able to function with his usual activities over this time.In July 2020 he dislocated …

Diffuse large B-cell lymphoma presenting as LUTS: Clinical practice points Open

Soum D. Lokeshwar, Syed N. Rahman, Jamil Syed, Thomas F. Monaghan, Benjamin Press , et al. · 2021

Challenging Cases in Urothelial Cancer: Case 23 Open

Mark S. Soloway, Neil A. Abrahams · 2021

Challenging Cases in Urothelial Cancer: Case 21 Open

Mark S. Soloway · 2021

This is a 65-year-old current and longtime cigarette smoker who presented to me with an 8 month history of intermittent gross hematuria and a diagnosis of muscle invasive urothelial cancer of the bladder.He has type 2 diabetes mellitus.He …

Challenging Cases in Urothelial Cancer: Case 20 Open

Mark S. Soloway · 2021

Challenging Cases in Urothelial Cancer Open

Mark S. Soloway, Neil A. Abrahams · 2021

[This corrects the article DOI: 10.3233/BLC-200004.].

Challenging Cases in Urothelial Cancer: Case 18 Open

Mark S. Soloway · 2021

[This corrects the article DOI: 10.3233/BLC-200009.].

Challenging Cases in Urothelial Cancer Open

Mark S. Soloway · 2021

[This corrects the article DOI: 10.3233/BLC-200001.].

Challenging Cases in Urothelial Cancer: Case 17 Open

Mark S. Soloway · 2021

[This corrects the article DOI: 10.3233/BLC-200007.].

Challenging Cases in Urothelial Cancer: Case 19 Open

Mark S. Soloway, Neil A. Abrahams · 2021

RS is an 81 year old man with a history of low and high grade Ta bladder cancer in 2010.He was free of any bladder cancer until 2020.He had routine office cystoscopy and cytology through 2016 with urinalysis only from 2016 to 2020.He has c…

Challenging Cases in Urothelial Cancer: Case 18 Open

Mark S. Soloway · 2020

Molecular targeting of renal cell carcinoma by an oral combination Open

Andre R. Jordan, Jiaojiao Wang, Travis J. Yates, Sarrah L. Hasanali, Soum D. Lokeshwar , et al. · 2020

The 5-year survival rate of patients with metastatic renal cell carcinoma (mRCC) is <12% due to treatment failure. Therapeutic strategies that overcome resistance to modestly effective drugs for mRCC, such as sorafenib (SF), could improve …

Challenging Cases in Urothelial Cancer Open

Mark S. Soloway, Neil A. Abrahams · 2020

Challenging Cases in Urothelial Cancer Open

Mark S. Soloway · 2020

Challenging Cases in Urothelial Cancer Open

Mark S. Soloway · 2019

Mark S. Soloway YOU? Author Swipe